Copyright Reports & Markets. All rights reserved.

Global Sustained Release Ophthalmic Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Sustained Release Ophthalmic Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Implants
    • 1.3.3 Punctal Plug
    • 1.3.4 Liposome
    • 1.3.5 In Situ Gel
  • 1.4 Market Analysis by Release Mechanism
    • 1.4.1 Overview: Global Sustained Release Ophthalmic Drugs Consumption Value by Release Mechanism: 2021 Versus 2025 Versus 2032
    • 1.4.2 Diffusion Controlled Drug
    • 1.4.3 Degradation Controlled Drug
    • 1.4.4 Swelling Controlled Drug
    • 1.4.5 Stimuli Responsive Drug
  • 1.5 Market Analysis by Application
    • 1.5.1 Overview: Global Sustained Release Ophthalmic Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 Cataract Therapy
    • 1.5.3 Glaucoma Therapy
    • 1.5.4 Dry Eye Disease Therapy
    • 1.5.5 Others
  • 1.6 Global Sustained Release Ophthalmic Drugs Market Size & Forecast
    • 1.6.1 Global Sustained Release Ophthalmic Drugs Consumption Value (2021 & 2025 & 2032)
    • 1.6.2 Global Sustained Release Ophthalmic Drugs Sales Quantity (2021-2032)
    • 1.6.3 Global Sustained Release Ophthalmic Drugs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 EyePoint
    • 2.1.1 EyePoint Details
    • 2.1.2 EyePoint Major Business
    • 2.1.3 EyePoint Sustained Release Ophthalmic Drugs Product and Services
    • 2.1.4 EyePoint Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 EyePoint Recent Developments/Updates
  • 2.2 AbbVie
    • 2.2.1 AbbVie Details
    • 2.2.2 AbbVie Major Business
    • 2.2.3 AbbVie Sustained Release Ophthalmic Drugs Product and Services
    • 2.2.4 AbbVie Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 AbbVie Recent Developments/Updates
  • 2.3 Ocular Therapeutix
    • 2.3.1 Ocular Therapeutix Details
    • 2.3.2 Ocular Therapeutix Major Business
    • 2.3.3 Ocular Therapeutix Sustained Release Ophthalmic Drugs Product and Services
    • 2.3.4 Ocular Therapeutix Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Ocular Therapeutix Recent Developments/Updates
  • 2.4 Neurotech Pharmaceuticals
    • 2.4.1 Neurotech Pharmaceuticals Details
    • 2.4.2 Neurotech Pharmaceuticals Major Business
    • 2.4.3 Neurotech Pharmaceuticals Sustained Release Ophthalmic Drugs Product and Services
    • 2.4.4 Neurotech Pharmaceuticals Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Neurotech Pharmaceuticals Recent Developments/Updates
  • 2.5 Santen Pharmaceutical
    • 2.5.1 Santen Pharmaceutical Details
    • 2.5.2 Santen Pharmaceutical Major Business
    • 2.5.3 Santen Pharmaceutical Sustained Release Ophthalmic Drugs Product and Services
    • 2.5.4 Santen Pharmaceutical Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Santen Pharmaceutical Recent Developments/Updates
  • 2.6 Clearside Biomedical
    • 2.6.1 Clearside Biomedical Details
    • 2.6.2 Clearside Biomedical Major Business
    • 2.6.3 Clearside Biomedical Sustained Release Ophthalmic Drugs Product and Services
    • 2.6.4 Clearside Biomedical Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Clearside Biomedical Recent Developments/Updates
  • 2.7 PolyActiva
    • 2.7.1 PolyActiva Details
    • 2.7.2 PolyActiva Major Business
    • 2.7.3 PolyActiva Sustained Release Ophthalmic Drugs Product and Services
    • 2.7.4 PolyActiva Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 PolyActiva Recent Developments/Updates
  • 2.8 Kodiak Sciences
    • 2.8.1 Kodiak Sciences Details
    • 2.8.2 Kodiak Sciences Major Business
    • 2.8.3 Kodiak Sciences Sustained Release Ophthalmic Drugs Product and Services
    • 2.8.4 Kodiak Sciences Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Kodiak Sciences Recent Developments/Updates
  • 2.9 Adverum
    • 2.9.1 Adverum Details
    • 2.9.2 Adverum Major Business
    • 2.9.3 Adverum Sustained Release Ophthalmic Drugs Product and Services
    • 2.9.4 Adverum Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Adverum Recent Developments/Updates
  • 2.10 Bausch + Lomb
    • 2.10.1 Bausch + Lomb Details
    • 2.10.2 Bausch + Lomb Major Business
    • 2.10.3 Bausch + Lomb Sustained Release Ophthalmic Drugs Product and Services
    • 2.10.4 Bausch + Lomb Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Bausch + Lomb Recent Developments/Updates
  • 2.11 Kanghong
    • 2.11.1 Kanghong Details
    • 2.11.2 Kanghong Major Business
    • 2.11.3 Kanghong Sustained Release Ophthalmic Drugs Product and Services
    • 2.11.4 Kanghong Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Kanghong Recent Developments/Updates
  • 2.12 Ocumension
    • 2.12.1 Ocumension Details
    • 2.12.2 Ocumension Major Business
    • 2.12.3 Ocumension Sustained Release Ophthalmic Drugs Product and Services
    • 2.12.4 Ocumension Sustained Release Ophthalmic Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Ocumension Recent Developments/Updates

3 Competitive Environment: Sustained Release Ophthalmic Drugs by Manufacturer

  • 3.1 Global Sustained Release Ophthalmic Drugs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Sustained Release Ophthalmic Drugs Revenue by Manufacturer (2021-2026)
  • 3.3 Global Sustained Release Ophthalmic Drugs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Sustained Release Ophthalmic Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Sustained Release Ophthalmic Drugs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Sustained Release Ophthalmic Drugs Manufacturer Market Share in 2025
  • 3.5 Sustained Release Ophthalmic Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 Sustained Release Ophthalmic Drugs Market: Region Footprint
    • 3.5.2 Sustained Release Ophthalmic Drugs Market: Company Product Type Footprint
    • 3.5.3 Sustained Release Ophthalmic Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Sustained Release Ophthalmic Drugs Market Size by Region
    • 4.1.1 Global Sustained Release Ophthalmic Drugs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Sustained Release Ophthalmic Drugs Consumption Value by Region (2021-2032)
    • 4.1.3 Global Sustained Release Ophthalmic Drugs Average Price by Region (2021-2032)
  • 4.2 North America Sustained Release Ophthalmic Drugs Consumption Value (2021-2032)
  • 4.3 Europe Sustained Release Ophthalmic Drugs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Sustained Release Ophthalmic Drugs Consumption Value (2021-2032)
  • 4.5 South America Sustained Release Ophthalmic Drugs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Sustained Release Ophthalmic Drugs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Sustained Release Ophthalmic Drugs Sales Quantity by Type (2021-2032)
  • 5.2 Global Sustained Release Ophthalmic Drugs Consumption Value by Type (2021-2032)
  • 5.3 Global Sustained Release Ophthalmic Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Sustained Release Ophthalmic Drugs Sales Quantity by Application (2021-2032)
  • 6.2 Global Sustained Release Ophthalmic Drugs Consumption Value by Application (2021-2032)
  • 6.3 Global Sustained Release Ophthalmic Drugs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Sustained Release Ophthalmic Drugs Sales Quantity by Type (2021-2032)
  • 7.2 North America Sustained Release Ophthalmic Drugs Sales Quantity by Application (2021-2032)
  • 7.3 North America Sustained Release Ophthalmic Drugs Market Size by Country
    • 7.3.1 North America Sustained Release Ophthalmic Drugs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Sustained Release Ophthalmic Drugs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Sustained Release Ophthalmic Drugs Sales Quantity by Type (2021-2032)
  • 8.2 Europe Sustained Release Ophthalmic Drugs Sales Quantity by Application (2021-2032)
  • 8.3 Europe Sustained Release Ophthalmic Drugs Market Size by Country
    • 8.3.1 Europe Sustained Release Ophthalmic Drugs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Sustained Release Ophthalmic Drugs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Sustained Release Ophthalmic Drugs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Sustained Release Ophthalmic Drugs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Sustained Release Ophthalmic Drugs Market Size by Region
    • 9.3.1 Asia-Pacific Sustained Release Ophthalmic Drugs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Sustained Release Ophthalmic Drugs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Sustained Release Ophthalmic Drugs Sales Quantity by Type (2021-2032)
  • 10.2 South America Sustained Release Ophthalmic Drugs Sales Quantity by Application (2021-2032)
  • 10.3 South America Sustained Release Ophthalmic Drugs Market Size by Country
    • 10.3.1 South America Sustained Release Ophthalmic Drugs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Sustained Release Ophthalmic Drugs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Sustained Release Ophthalmic Drugs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Sustained Release Ophthalmic Drugs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Sustained Release Ophthalmic Drugs Market Size by Country
    • 11.3.1 Middle East & Africa Sustained Release Ophthalmic Drugs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Sustained Release Ophthalmic Drugs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Sustained Release Ophthalmic Drugs Market Drivers
  • 12.2 Sustained Release Ophthalmic Drugs Market Restraints
  • 12.3 Sustained Release Ophthalmic Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Sustained Release Ophthalmic Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Sustained Release Ophthalmic Drugs
  • 13.3 Sustained Release Ophthalmic Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Sustained Release Ophthalmic Drugs Typical Distributors
  • 14.3 Sustained Release Ophthalmic Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Sustained Release Ophthalmic Drugs market size was valued at US$ 1543 million in 2025 and is forecast to a readjusted size of US$ 2595 million by 2032 with a CAGR of 7.3% during review period.
    Sustained Release Ophthalmic Drugs refer to a general category of pharmaceutical products that utilize modern formulation technologies or medical device platforms to continuously release active pharmaceutical ingredients to the eye at a controlled rate, thereby extending the duration of therapeutic action. Unlike conventional eye drops which have short residence time on the ocular surface and low bioavailability, Sustained Release Ophthalmic Drugs form drug depots within the eye by overcoming complex physiological barriers such as the corneal barrier and tear clearance system. This technology platform can extend traditional therapeutic regimens requiring multiple daily administrations to single administrations lasting weeks, months, or even longer periods. From an industrial attribute perspective, Sustained Release Ophthalmic Drugs sit at the intersection of pharmaceutics, polymer materials science, bioengineering, and clinical ophthalmology, encompassing multiple dosage forms and device formats including implants, punctal plugs, in situ gels, nanosuspensions, and drug eluting contact lenses. Their core value lies in significantly improving patient medication adherence, reducing the risk of side effects from frequent administration, and achieving precise drug delivery to target sites.
    Market Development Opportunities and Main Drivers
    Global population aging and the increasing prevalence of chronic eye diseases directly drive clinical demand for long acting therapeutic solutions. The accelerated approval pathways of the US Food and Drug Administration and the European Medicines Agency provide policy support for innovative products. The application of biodegradable polymers, nanotechnology, and smart stimuli responsive materials has significantly improved system controllability and safety. Allergan’s Durysta, as the first approved intracameral sustained release implant, received US Food and Drug Administration approval for open angle glaucoma. Alcon, Roche, and Santen have built dense patent portfolios around sustained release devices and biologics.
    Market Challenges and Risks
    Sustained Release Ophthalmic Drugs face core challenges including long product development cycles and high regulatory barriers. The review pathway for combination products is complex, requiring simultaneous fulfillment of both drug safety and medical device performance requirements. Some non biodegradable implants require surgical removal after drug depletion, increasing patient risk and healthcare burden. The supply of precision manufacturing processes and high purity polymer excipients is relatively concentrated, creating sustained cost control pressure. Marketed products face technology substitution risk, as exemplified by the OTX TP punctal plug, which was discontinued after failing to meet clinical trial endpoints. Furthermore, the non adjustable dosing nature of sustained release systems imposes limitations on personalized treatment, as once implanted it is difficult to adjust or terminate drug delivery.
    Downstream Demand Trends
    The glaucoma treatment field shows the most urgent need to reduce daily eye drop dependence, with intracameral implants and punctal plugs becoming the primary technology pathways. Patients with age related macular degeneration and diabetic retinopathy show growing demand for intravitreal sustained release implants, as existing anti vascular endothelial growth factor therapies require monthly injections and suffer from poor patient compliance. Anterior segment diseases such as dry eye disease and postoperative inflammation control are driving clinical adoption of conjunctival fornix inserts and drug eluting contact lenses. Notably, gene therapy and cell therapy are converging with sustained release delivery technologies, and encapsulated cell therapy implants have entered clinical use, capable of secreting therapeutic proteins over the long term.
    Regional Trends
    The North American market, with its mature regulatory approval pathways, comprehensive reimbursement coverage, and concentration of major innovative companies, leads in the commercialization of Sustained Release Ophthalmic Drugs. The European market, influenced by deepening aging demographics and shifting healthcare spending priorities, shows strong demand for cost effective long acting therapeutic solutions. The Asia Pacific region, benefiting from improved ophthalmic diagnostic and treatment capabilities and enhanced patient purchasing power in countries including China and India, is emerging as a growth region. Santen Pharmaceutical and other companies are accelerating product regional penetration by focusing on the Asian market and conducting local clinical studies.
    This report is a detailed and comprehensive analysis for global Sustained Release Ophthalmic Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Sustained Release Ophthalmic Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Sustained Release Ophthalmic Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Sustained Release Ophthalmic Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Sustained Release Ophthalmic Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Sustained Release Ophthalmic Drugs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Sustained Release Ophthalmic Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include EyePoint, AbbVie, Ocular Therapeutix, Neurotech Pharmaceuticals, Santen Pharmaceutical, Clearside Biomedical, PolyActiva, Kodiak Sciences, Adverum, Bausch + Lomb, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Sustained Release Ophthalmic Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Implants
    Punctal Plug
    Liposome
    In Situ Gel
    Market segment by Release Mechanism
    Diffusion Controlled Drug
    Degradation Controlled Drug
    Swelling Controlled Drug
    Stimuli Responsive Drug
    Market segment by Application
    Cataract Therapy
    Glaucoma Therapy
    Dry Eye Disease Therapy
    Others
    Major players covered
    EyePoint
    AbbVie
    Ocular Therapeutix
    Neurotech Pharmaceuticals
    Santen Pharmaceutical
    Clearside Biomedical
    PolyActiva
    Kodiak Sciences
    Adverum
    Bausch + Lomb
    Kanghong
    Ocumension
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Sustained Release Ophthalmic Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Sustained Release Ophthalmic Drugs, with price, sales quantity, revenue, and global market share of Sustained Release Ophthalmic Drugs from 2021 to 2026.
    Chapter 3, the Sustained Release Ophthalmic Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Sustained Release Ophthalmic Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Sustained Release Ophthalmic Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Sustained Release Ophthalmic Drugs.
    Chapter 14 and 15, to describe Sustained Release Ophthalmic Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now